bigram

This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

bigram	frequency
stem cell	3145
cell transplantation	2286
bone marrow	1445
hematopoietic stem	1319
mg kg	971
median age	915
peripheral blood	895
overall survival	819
acute gvhd	751
conditioning regimen	751
patients received	750
chronic gvhd	747
host disease	727
cd cells	641
median follow	621
one patient	604
allogeneic hematopoietic	602
stem cells	590
median time	526
free survival	502
risk factors	502
cd cd	487
transplant recipients	475
cell transplant	458
nk cells	458
high risk	455
allogeneic stem	449
gvhd prophylaxis	442
cord blood	423
allogeneic hsct	418
hsct recipients	404
marrow transplantation	394
unrelated donor	379
two patients	375
cumulative incidence	370
mg dl	356
complete remission	354
flow cytometry	342
blood stem	325
graft failure	320
design method	318
pediatric patients	309
graft versus	304
intensity conditioning	302
related mortality	294
patients receiving	291
hematopoietic cell	283
myeloablative conditioning	282
multiple myeloma	282
versus host	278
reduced intensity	274
multivariate analysis	269
grade ii	263
acute myeloid	262
myeloid leukemia	261
patients undergoing	260
matched unrelated	256
years old	256
autologous stem	252
donor chimerism	251
primary immunodeficiency	249
respiratory tract	248
conditioning regimens	247
three patients	247
cmv reactivation	244
significantly higher	233
case report	229
united states	229
unrelated donors	228
immune reconstitution	227
relapse mortality	225
kg day	225
adult patients	221
acute leukemia	221
viral infections	218
cd cell	217
immune deficiency	216
statistically significant	216
four patients	216
acute lymphoblastic	211
ng ml	211
increased risk	211
patients treated	210
patients developed	206
cd ra	205
retrospective study	204
grade iii	200
significant difference	199
adverse events	199
marrow transplant	198
lymphoblastic leukemia	198
side effects	198
cell source	198
nk cell	197
acute graft	193
introduction background	193
infectious complications	192
five patients	185
months post	184
high dose	182
patients died	182
hsct patients	177
year os	177
risk factor	176
cell dose	174
hematologic malignancies	171
cell lymphoma	166
respiratory syncytial	165
university hospital	164
combined immunodeficiency	164
haematopoietic stem	164
disease status	163
cmv infection	162
syncytial virus	160
exome sequencing	160
dose chemotherapy	159
hematological malignancies	158
immune system	157
matched sibling	157
patients without	156
neutrophil engraftment	155
lung transplant	153
sibling donor	152
states background	150
patients transplanted	149
median number	149
old male	149
hodgkin lymphoma	148
matched related	147
cells kg	146
cell depletion	146
sickle cell	145
body irradiation	145
clinical trial	144
chronic graft	144
platelet engraftment	143
well tolerated	143
significant differences	142
autologous hsct	142
fungal infections	142
bronchiolitis obliterans	140
two groups	140
mean age	138
mycophenolate mofetil	138
one year	137
cell count	137
six patients	137
retrospective analysis	136
ex vivo	136
clinical trials	135
patient developed	134
lower respiratory	134
total body	133
abstract case	132
year old	132
report text	132
disease progression	132
respiratory viruses	132
lung disease	131
post transplant	130
aml patients	129
respiratory failure	129
patients underwent	127
risk patients	126
platelet count	126
mononuclear cells	125
immunocompromised patients	125
mixed chimerism	125
identical sibling	125
univariate analysis	124
aplastic anemia	124
prospective study	124
consecutive patients	123
least one	122
viral load	122
significantly lower	122
infectious diseases	122
old female	122
cell lines	122
healthy donors	122
days post	121
age years	121
long term	121
year overall	121
allogeneic sct	120
none declared	120
chart review	120
replacement therapy	120
related donor	120
among patients	120
control group	119
pts received	119
recurrent infections	119
umbilical cord	119
immune dysregulation	118
cell disease	118
cell therapy	118
residual disease	117
full donor	117
patient died	116
marrow failure	116
single center	115
transplant related	115
respiratory virus	114
eight patients	113
myelodysplastic syndrome	113
medical center	113
invasive fungal	113
iv acute	112
whole exome	111
post hsct	111
progressive disease	111
transplant patients	111
partial response	111
allogeneic transplantation	110
retrospectively analyzed	110
complete response	109
mortality rate	109
severe combined	109
grade i	108
clinical features	108
cell counts	108
haploidentical donor	108
hemorrhagic cystitis	108
genetic testing	107
sos vod	107
immunosuppressive therapy	107
response rate	107
relapse rate	106
allogeneic hct	106
autosomal recessive	106
mm patients	106
bacterial infections	106
seven patients	105
occlusive disease	104
patients showed	103
line therapy	102
nine patients	102
fi rst	102
first year	102
cell depleted	101
pg ml	100
induction therapy	100
disease relapse	100
donor type	100
first days	100
previously reported	99
family history	99
median duration	99
blood cell	99
abdominal pain	98
supportive care	98
relapse incidence	98
poor prognosis	97
cell proliferation	97
immune response	97
copies ml	97
clinical presentation	97
based conditioning	96
patients aged	96
virus infections	96
cell receptor	95
healthy controls	95
gvhd grade	95
febrile neutropenia	95
transplanted patients	95
graft rejection	95
haploidentical hsct	94
last follow	94
significantly associated	94
underwent hsct	94
cvid patients	94
virus infection	93
donor lymphocyte	93
solid tumors	93
partial remission	92
solid organ	92
pulmonary complications	92
higher risk	92
retrospective chart	92
median cd	92
newly diagnosed	91
treatment option	91
curative treatment	91
performed using	90
transplant cyclophosphamide	90
data suggest	90
following allogeneic	89
primary immunodeficiencies	89
cd count	88
prophylaxis consisted	88
survival rate	88
underwent allogeneic	88
autologous hematopoietic	88
medical records	88
patient received	88
respiratory viral	88
time points	87
granulomatous disease	87
fungal infection	87
common variable	87
patients achieved	86
tract infections	86
disease free	86
cells ul	85
case series	85
informed consent	84
cancer patients	84
blood cells	84
acute respiratory	84
patients diagnosed	84
body weight	84
minimal residual	84
natural killer	84
idiopathic pneumonia	83
antithymocyte globulin	83
within days	83
cell subsets	83
patients presented	83
underlying disease	83
survival rates	83
following hsct	83
red blood	82
hla matched	82
signifi cant	82
whole blood	82
relapsed refractory	81
nervous system	81
patient population	80
intensive care	80
respiratory infections	80
low dose	80
primary immune	80
generation sequencing	80
chronic granulomatous	80
cell lymphopenia	80
ct scan	80
clinical manifestations	80
pneumonia syndrome	79
active disease	79
blood samples	79
neutrophil count	79
barr virus	79
related complications	79
viral infection	78
lymphocyte subsets	78
undergoing hsct	78
salvage therapy	78
central nervous	78
haploidentical transplantation	78
died due	78
monoclonal antibody	77
undergoing allogeneic	77
analysis showed	77
upper respiratory	77
clinical course	76
significantly increased	76
neutrophil recovery	75
significantly different	75
hla identical	75
bk virus	75
newborn screening	75
patients experienced	75
immunoglobulin replacement	75
variable immunodeficiency	75
disease control	75
clinical outcomes	75
myeloma patients	75
invasive aspergillosis	74
lymph node	74
higher incidence	74
prospective studies	74
treatment related	73
lymph nodes	73
day post	73
severe infections	73
one case	73
antiviral therapy	73
mechanical ventilation	72
mismatched unrelated	72
early diagnosis	72
lymphocyte count	72
included patients	72
blood transplantation	72
within months	72
autoimmune diseases	72
patients engrafted	72
pulmonary function	72
study period	72
antibody deficiency	72
blood cultures	72
two years	72
parainfluenza virus	71
two cases	71
allogeneic bone	71
sibling donors	71
extensive chronic	71
statistical significance	71
related donors	71
signifi cantly	71
line treatment	70
gene expression	70
graft source	70
case reports	70
developed acute	69
declare background	69
fludarabine mg	69
year survival	69
pediatric oncology	69
oral mucositis	69
primary endpoint	68
factors associated	68
human metapneumovirus	68
refractory disease	68
thymocyte globulin	68
results suggest	68
important role	68
treatment options	68
clinical practice	68
hemolytic anemia	68
cmv disease	67
term survival	67
term follow	67
autologous transplantation	67
statistical analysis	67
risk group	67
prognostic factors	67
cell numbers	67
first line	67
antifungal prophylaxis	67
matched donor	67
cell reconstitution	67
allogeneic haematopoietic	66
lymphoma patients	66
diagnostic criteria	66
second transplant	66
normal range	66
cell function	66
pid patients	66
median os	66
dock deficiency	66
remaining patients	66
progenitor cells	65
may also	65
phase ii	65
intravenous immunoglobulin	65
cohort study	65
chain reaction	65
significantly reduced	64
polymerase chain	64
renal failure	64
phase i	64
renal function	64
neutropenic patients	64
significant increase	64
induction chemotherapy	64
secondary graft	63
platelet recovery	63
organizing pneumonia	63
severe acute	63
extracorporeal photopheresis	63
year post	63
ebv reactivation	63
months later	63
previous studies	63
logistic regression	62
cd ro	62
respiratory distress	62
center experience	62
septic shock	62
weight loss	62
developed grade	62
inclusion criteria	62
malignant disease	62
cyclophosphamide mg	61
achieved cr	61
haploidentical donors	61
clinical characteristics	61
bronchoalveolar lavage	61
leukemia patients	61
late effects	61
old boy	61
gene therapy	61
median days	60
major cause	60
old girl	60
lung injury	60
therapeutic option	60
care unit	59
grade iv	59
analysis revealed	59
present study	59
clinical outcome	59
lung transplantation	59
antifungal therapy	59
adenovirus infection	59
progression free	59
vod sos	59
general population	59
previously described	59
cd kg	59
organ failure	59
ten patients	59
clinical data	59
copy number	59
absolute neutrophil	59
regimen consisted	58
corticosteroid therapy	58
clinical symptoms	58
melphalan mg	58
study group	58
mg day	58
pediatric hematology	58
advanced disease	58
positive cells	58
adverse effects	58
haploidentical stem	58
successfully treated	58
received hsct	57
tract infection	57
atg group	57
medical history	57
hemophagocytic lymphohistiocytosis	57
underwent allo	57
high incidence	57
retrospectively reviewed	57
working party	57
last years	57
preparative regimen	57
high mortality	57
older patients	57
years post	56
otitis media	56
radiation therapy	56
median day	56
diffuse large	56
three months	56
health care	56
stimulating factor	56
infection control	56
icu admission	56
iron overload	56
high rate	56
cell mobilization	56
high levels	56
next generation	56
oncology patients	56
alternative donor	55
patient presented	55
atopic dermatitis	55
gastrointestinal tract	55
severe cgvhd	55
blood mononuclear	55
white blood	55
family members	54
per day	54
tract disease	54
severe chronic	54
primary graft	54
organ transplant	54
peripheral stem	54
low risk	54
iv agvhd	54
agvhd grade	54
severe gvhd	54
doc id	54
cord uid	54
family donor	54
effective treatment	54
kg cd	54
male patients	54
elderly patients	54
aerosolized ribavirin	54
protein expression	54
may lead	53
respiratory symptoms	53
immunoglobulin levels	53
confidence interval	53
overall response	53
per kg	53
maintenance therapy	53
cell transplants	53
salvage treatment	53
autosomal dominant	53
two weeks	53
refractory acute	53
iu ml	53
significant reduction	53
clinical response	53
ric allo	53
inflammatory bowel	52
allogeneic transplant	52
consecutive days	52
lymphocyte infusion	52
physical examination	52
dendritic cells	52
bowel disease	52
unrelated cord	52
severe aplastic	52
developed chronic	52
monoclonal antibodies	52
diffuse alveolar	51
obliterans syndrome	51
haematological malignancies	51
older age	51
widely used	51
transplant recipient	51
retrospective review	51
first time	51
cell development	51
opportunistic infections	51
significantly better	51
mesenchymal stem	51
compound heterozygous	51
patients relapsed	51
patient characteristics	51
treated patients	51
autologous sct	51
organ transplantation	50
patient age	50
viral reactivation	50
malignant diseases	50
scid patients	50
significant risk	50
pts died	50
trial registry	50
recent years	50
autoimmune disease	50
specific antibody	49
second line	49
combined immune	49
lung function	49
haploidentical transplant	49
performance status	49
thalassemia major	49
deficient patients	49
immune cells	49
childhood cancer	49
received myeloablative	49
clinical phenotype	49
myeloid leukaemia	49
neutropenic fever	49
clinically significant	49
transplant period	49
tyrosine kinase	48
skin lesions	48
cd depleted	48
risk acute	48
bu cy	48
trend towards	48
overall mortality	48
early post	48
platelet counts	48
pediatric cancer	47
sinopulmonary infections	47
potentially curative	47
graft function	47
igg levels	47
one patients	47
related toxicity	47
red cell	47
cik cells	47
marrow biopsy	47
autologous peripheral	47
alveolar hemorrhage	47
infectious disease	47
human herpesvirus	47
significant morbidity	47
hazard ratio	47
hematologic malignancy	47
clinical immunology	47
obstruction syndrome	47
may help	47
year cumulative	47
lymphoproliferative disease	47
xiap deficiency	47
cox regression	47
sinusoidal obstruction	47
sanger sequencing	47
ric regimen	47
developed severe	47
cell replete	47
first months	47
growth factor	47
commonly used	47
national institute	47
cells showed	46
per patient	46
chronic myeloid	46
cell recovery	46
safety profile	46
flow cytometric	46
lymphocyte infusions	46
curative option	46
study included	46
gvhd occurred	46
stable disease	46
time pcr	46
median dose	46
eleven patients	46
hematology oncology	46
patients may	46
complete donor	46
patients suffering	46
cmv viremia	46
mortality rates	46
regression analysis	46
cell infusion	46
two months	45
calcineurin inhibitors	45
kg bw	45
successful treatment	45
pilot study	45
response rates	45
text introduction	45
hct recipients	45
central venous	45
thrombotic microangiopathy	45
immune deficiencies	45
adoptive immunotherapy	45
lung biopsy	45
determine whether	45
immune responses	44
term outcome	44
sot recipients	44
function tests	44
serum levels	44
cell populations	44
influenza virus	44
underwent asct	44
soft tissue	44
findings suggest	44
liver disease	44
low igg	44
low cd	44
risk aml	44
immune recovery	44
cells infused	44
cell viability	44
national institutes	44
pet ct	44
clinical improvement	44
weight gain	44
immunosuppressive treatment	44
pediatric population	43
transplant outcomes	43
young adults	43
risk score	43
improved survival	43
lymphoproliferative disorders	43
per year	43
conventional chemotherapy	43
increased susceptibility	43
aldrich syndrome	43
nucleated cells	43
tumor necrosis	43
one hundred	43
one month	43
cells mm	43
cells per	43
liver transplant	43
relapse risk	42
research funding	42
young children	42
significantly decreased	42
year period	42
significant impact	42
stage iii	42
positive patients	42
six months	42
immune cell	42
case presentation	42
antibiotic therapy	42
differential diagnosis	42
autologous transplant	42
preliminary results	42
rank test	42
achieved complete	42
immune suppression	42
cell products	42
disclosure background	42
aged years	42
preemptive therapy	42
average age	41
following hematopoietic	41
cancer center	41
preliminary data	41
transplant centers	41
cd lymphocytes	41
th percentile	41
blood count	41
class i	41
interstitial lung	41
donor cells	41
total number	41
within normal	41
plasma cells	41
i ii	41
cd positive	41
inflammatory response	40
vs days	40
pediatric hsct	40
endothelial cells	40
curative therapy	40
cell line	40
late onset	40
rsv infection	40
surviving patients	40
cgd patients	40
donor cell	40
many patients	40
donor source	40
may contribute	40
main cause	40
significant improvement	40
ebv infection	40
following transplantation	40
term survivors	40
cd expression	40
retrospective cohort	40
cytokine release	40
patients required	40
missense mutation	40
donor age	40
prognostic factor	40
sample size	40
chimeric antigen	40
significantly improved	40
intermediate risk	39
donor recipient	39
liver failure	39
cell population	39
mobilized peripheral	39
time period	39
based regimen	39
transplant outcome	39
first complete	39
side effect	39
carv infection	39
limited data	39
recurrent sinopulmonary	39
risk cytogenetics	39
liver biopsy	39
transcription factor	39
cells expressing	39
salvage chemotherapy	39
low incidence	39
female patients	39
chemotherapy followed	39
median survival	39
autoimmune cytopenias	39
younger patients	39
controlled trial	39
post transplantation	39
high grade	39
received allo	38
conditioning therapy	38
switched memory	38
cell activation	38
patients included	38
class ii	38
effector memory	38
steroid refractory	38
received allogeneic	38
nonrelapse mortality	38
fully matched	38
first case	38
multicenter study	38
relapsed disease	38
standard treatment	38
eligible patients	38
engraftment failure	38
inborn errors	38
systematic review	38
centre experience	38
influenza vaccine	38
cell collection	38
amino acid	38
male patient	38
combination therapy	38
lymphocyte counts	38
patients affected	38
event free	38
patient experienced	38
release syndrome	37
better os	37
stromal cells	37
patient underwent	37
longer follow	37
small number	37
poor outcome	37
treatment failure	37
herpes simplex	37
il rg	37
multiorgan failure	37
nd allo	37
necrosis factor	37
entire cohort	37
liver transplantation	37
paediatric patients	37
colony stimulating	37
chronic lymphocytic	37
age groups	37
quantitative pcr	37
analyzed patients	37
steroid treatment	36
significant decrease	36
ikbkb immune	36
ml min	36
engraftment occurred	36
patient showed	36
group compared	36
computed tomography	36
first day	36
still alive	36
mouse model	36
independently associated	36
specific cd	36
total dose	36
primary refractory	36
ige syndrome	36
family donors	36
multiple sclerosis	36
five years	36
children undergoing	36
jazz pharmaceuticals	36
serum ferritin	36
meier method	36
relapse rates	36
febrile episodes	36
breast cancer	36
igg mg	36
liver function	36
two different	36
primary disease	35
noninfectious pulmonary	35
randomized trial	35
trough levels	35
influenza vaccination	35
hepatic veno	35
early onset	35
recent studies	35
chronic lung	35
low levels	35
severe sepsis	35
transplant characteristics	35
sequencing revealed	35
absolute lymphocyte	35
submission id	35
every weeks	35
treatment modality	35
oral cavity	35
cgvhd patients	35
function mutations	35
igg level	35
cell death	35
blood pressure	35
cd selected	35
mds patients	35
effi cacy	35
serious adverse	35
twelve patients	35
days following	35
median interval	35
young adult	35
distress syndrome	35
high rates	34
different time	34
lower incidence	34
intensive chemotherapy	34
large cohort	34
treatment strategies	34
pulmonary disease	34
ecp treatment	34
abstract already	34
dna repair	34
disease risk	34
biopsy revealed	34
severe neutropenia	34
already published	34
hematopoietic cells	34
hospital stay	34
steroid therapy	34
phase iii	34
time point	34
cytokine production	34
pts receiving	34
inflammatory cytokines	34
th cells	34
infused cd	34
liposomal amphotericin	34
comorbidity index	34
life threatening	34
retrospectively evaluated	34
mcg kg	34
antiviral treatment	34
skin infections	34
immunodeficiency diseases	34
adverse reactions	34
cumulative incidences	34
research center	34
patient cohort	34
granulocyte colony	34
leukemic cells	34
also observed	34
term outcomes	33
blood culture	33
nonmalignant diseases	33
also found	33
lymphocytic leukemia	33
complete resolution	33
therapeutic options	33
serum igg	33
patients reported	33
short course	33
text background	33
higher rate	33
acute chest	33
antimicrobial therapy	33
single institution	33
pathogenic variant	33
previously healthy	33
data indicate	33
three groups	33
liver enzymes	33
tumor cells	33
defi ned	33
parenteral nutrition	33
even though	33
autoimmune hemolytic	33
results demonstrate	33
study population	33
post sct	33
gvl effect	32
ewing sarcoma	32
surface expression	32
antibody deficiencies	32
antibiotic prophylaxis	32
one week	32
innate immune	32
leading cause	32
female donor	32
kidney injury	32
calculated using	32
myeloablative allogeneic	32
plasma levels	32
allogenic hsct	32
dose melphalan	32
donor lymphocytes	32
adoptive transfer	32
cells mcl	32
alternative donors	32
phase study	32
patients will	32
evaluable patients	32
biopsy showed	32
recurrent respiratory	32
promising results	32
health status	32
single dose	32
progenitor cell	32
identify patients	32
solid tumor	32
oral mucosa	32
complete blood	32
patients following	32
study aimed	32
medical university	32
immunocompromised host	32
cd depletion	31
exact test	31
epithelial cells	31
potential risk	31
type i	31
hsct setting	31
cell responses	31
rabbit atg	31
dose therapy	31
heterozygous mutation	31
disorder characterized	31
authors declare	31
healthy individuals	31
infl uence	31
clinical diagnosis	31
elevated serum	31
chemotherapy alone	31
first month	31
study shows	31
cd dose	31
good partial	31
patient group	31
reduced toxicity	31
rv infection	31
dose cyclophosphamide	31
cells transplantation	31
multivariate cox	31
prophylactic antibiotics	31
identifi ed	31
two pts	31
pulmonary aspergillosis	31
gene mutation	31
cytogenetic risk	31
selected patients	31
diamond syndrome	31
cd ratio	31
independent risk	31
results indicate	31
without significant	31
severe disease	31
nkg dl	31
cell surface	31
higher cd	31
twice daily	31
clinical background	31
heterozygous mutations	31
chest syndrome	31
per week	31
remission status	31
group patients	31
disease following	31
serum creatinine	31
cancer survivors	31
regression model	31
received peripheral	31
mononuclear cell	31
hematopoietic recovery	31
staphylococcus aureus	31
genetic analysis	31
pathogenic variants	31
three years	31
antigen receptor	31
transplantation recipients	31
university medical	31
organ damage	30
lymphoproliferative disorder	30
developmental delay	30
haploidentical hematopoietic	30
mg ml	30
ct scans	30
cell sources	30
cmv dna	30
single centre	30
cell grafts	30
platelet transfusions	30
female patient	30
plasma cell	30
recurrent pneumonia	30
effector cells	30
myeloid malignancies	30
increased incidence	30
center study	30
data show	30
median overall	30
hsct may	30
bacterial infection	30
pulmonary fibrosis	30
recipient age	30
standard therapy	30
patients suffered	30
hearing loss	30
least months	30
male female	30
lymphocyte proliferation	30
interim analysis	30
significant association	30
may result	30
mean time	30
days vs	30
years overall	30
analyzed using	30
showed significantly	30
depleted grafts	30
allogeneic transplants	30
spectrum antibiotics	30
received dli	30
better outcome	30
second patient	30
second hsct	30
aml mds	30
normal levels	30
hematological recovery	29
diabetes mellitus	29
old man	29
less likely	29
molecular remission	29
aspergillus fumigatus	29
signaling pathway	29
case highlights	29
novel agents	29
growth factors	29
hsct using	29
laboratory findings	29
study showed	29
western blot	29
may develop	29
acute leukaemia	29
versushost disease	29
alpha beta	29
may provide	29
early mortality	29
post asct	29
chronic phase	29
disease burden	29
three pts	29
adverse event	29
receptor excision	29
immunosuppressive agents	29
fl udarabine	29
future studies	29
well established	29
without gvhd	29
critically ill	29
risk disease	29
pulmonary toxicity	29
electronic medical	29
negative impact	29
showed normal	29
renal impairment	29
patients responded	29
dose tbi	29
threatening complication	29
severe complication	29
mean number	29
cell doses	29
blood counts	29
effective therapy	29
decision making	29
within hours	29
pulmonary dysfunction	29
patients compared	29
disseminated disease	29
early relapse	29
fanconi anemia	29
developed agvhd	29
homozygous mutation	29
cox proportional	29
nod card	29
prospective randomized	28
competing risk	28
ebmt registry	28
uncertain significance	28
identical siblings	28
broad spectrum	28
close monitoring	28
plasma samples	28
simplex virus	28
current study	28
age group	28
remained stable	28
bloodstream infections	28
transplant complications	28
presenting cells	28
absolute number	28
mucocutaneous candidiasis	28
complete chimerism	28
intestinal gvhd	28
post hct	28
high level	28
cell differentiation	28
may improve	28
bleeding episodes	28
based gvhd	28
cr rate	28
pik cd	28
hematopoetic stem	28
relatively high	28
based regimens	28
haematopoietic cell	28
renal transplant	28
month old	28
early detection	28
kg body	28
acute kidney	28
immunodeficiency disease	28
cancer therapy	28
post allo	28
aplastic anaemia	28
poor mobilizers	28
factor viii	28
ctla ig	28
immune evaluation	28
blood transfusion	28
well known	28
disease recurrence	28
new york	27
beam group	27
clinical signs	27
chimerism analysis	27
medical record	27
ataxia telangiectasia	27
tbi gy	27
th day	27
unknown significance	27
transplantation unit	27
received mg	27
sct group	27
whereas patients	27
noninfectious ild	27
studies showed	27
single agent	27
lower risk	27
clinical findings	27
vivo expansion	27
poor graft	27
cellular therapy	27
patients years	27
brain mri	27
initial presentation	27
drug interactions	27
evans syndrome	27
renal disease	27
transplantation using	27
donor transplants	27
depleted haploidentical	27
high resolution	27
memory cells	27
stat gof	27
identified patients	27
results show	27
compared using	27
cell repertoire	27
early death	27
engraftment syndrome	27
may occur	27
reactive protein	27
higher number	27
pediatric patient	27
treatment modalities	27
dc leu	27
retrospectively analysed	27
myeloablative regimen	27
hla typing	27
multivariable analysis	27
calcineurin inhibitor	27
scoring system	27
lymphoproliferative syndrome	27
physical exam	27
antibody response	27
genomic dna	27
allogenic hematopoietic	27
affected patients	27
except one	27
graft vs	27
carv infections	27
fold increase	27
bloodstream infection	27
wide range	26
total cd	26
specific treatment	26
classified according	26
urinary tract	26
underwent autologous	26
acute renal	26
lupus erythematosus	26
antibody titers	26
achieve cr	26
days later	26
may represent	26
may cause	26
donor transplantation	26
skin biopsy	26
major complication	26
myelogenous leukemia	26
wilms tumor	26
relapsed aml	26
cell immunity	26
observational study	26
previously published	26
secondary endpoints	26
emptive therapy	26
statistically different	26
therapy may	26
adenovirus infections	26
autologous haematopoietic	26
developed cmv	26
specific ctls	26
hsct performed	26
clinical studies	26
patients presenting	26
therapeutic strategies	26
data regarding	26
early recognition	26
heavily pretreated	26
acute myelogenous	26
remains unclear	26
higher levels	26
protective effect	26
relapse free	26
ra cd	26
blood transplant	26
received chemotherapy	26
therapeutic approach	26
venoocclusive disease	26
retrospective studies	26
dose steroids	26
refractory agvhd	26
linked cgd	26
high frequency	26
common cause	26
consecutive adult	26
total nucleated	25
data collection	25
severe agvhd	25
community respiratory	25
viral respiratory	25
genetic diagnosis	25
last decade	25
liver toxicity	25
brain tumors	25
good response	25
pulmonary hemorrhage	25
immunosuppressive drugs	25
stat phosphorylation	25
poor outcomes	25
group vs	25
serum immunoglobulin	25
natural history	25
blood stream	25
mismatched related	25
hematological malignancy	25
spinal cord	25
metastatic disease	25
innate immunity	25
chemotherapeutic agents	25
patients met	25
spectra optia	25
mismatched donor	25
inkt cells	25
cd antibody	25
standard conditioning	25
average time	25
clinical impact	25
platelet transfusion	25
patients also	25
related disease	25
central memory	25
collected data	25
complement activation	25
better understand	25
three times	25
regression models	25
first patient	25
organ involvement	25
risk groups	25
past medical	25
factor receptor	25
gi tract	25
month post	25
kidney disease	25
times per	25
thrombocytopenic purpura	25
first report	25
induction treatment	25
statistical difference	25
overall incidence	25
least days	25
following allo	25
autologous hct	25
donor hsct	25
several studies	25
severe complications	25
pneumocystis jirovecii	25
undergoing allo	25
skin rash	25
cd bright	25
additional patients	25
cell transplantations	25
invasive pulmonary	25
streptococcus pneumoniae	25
refractory gvhd	25
transplant unit	25
cd selection	25
rhinovirus infections	25
evaluation revealed	25
sct recipients	25
haploidentical family	25
allogeneic peripheral	25
results obtained	25
early phase	25
fungal disease	25
targeted therapy	25
similar results	25
risk neuroblastoma	25
following autologous	25
mainly due	25
allo hsct	25
autoimmune disorders	25
haploidentical transplants	24
without evidence	24
inflammatory disease	24
transplantation cyclophosphamide	24
unmanipulated haploidentical	24
institutional review	24
receiving hsct	24
results showed	24
antibiotic treatment	24
descriptive statistics	24
cd car	24
thirteen patients	24
nhl patients	24
standard risk	24
study suggests	24
donor group	24
three cases	24
diseases working	24
leukemia effect	24
ii trial	24
cell chimerism	24
mrd negative	24
patient care	24
also significantly	24
laboratory data	24
sct patients	24
healthy donor	24
iii iv	24
lymphocyte subset	24
advanced age	24
surgical resection	24
related morbidity	24
serious complication	24
zoster virus	24
clinical significance	24
hematological diseases	24
will help	24
splice site	24
respiratory infection	24
revealed normal	24
conditioning consisted	24
encouraging results	24
european group	24
cmv pneumonia	24
uric acid	24
rsv infections	24
positive blood	24
cells ml	24
baseline characteristics	24
early childhood	24
hies patients	24
gata deficiency	24
months old	24
expression levels	24
rare disease	24
oral ribavirin	24
young patients	24
gene mutations	24
immune function	24
mouse models	24
threatening complications	24
developed gvhd	24
multivariate analyses	24
stage iv	24
incidence rate	24
dose corticosteroids	24
lentiviral vector	24
chronic diarrhea	24
excision circles	23
auto hsct	23
potential therapeutic	23
skin gvhd	23
significant correlation	23
lymphocyte subpopulations	23
refractory patients	23
ric regimens	23
hdt asct	23
predictive value	23
randomized controlled	23
systemic steroids	23
somatic mutations	23
several years	23
prospective trials	23
secondary malignancies	23
interquartile range	23
csf group	23
odds ratio	23
philadelphia chromosome	23
among children	23
heterogeneous group	23
see table	23
higher rates	23
genetic defect	23
whole cohort	23
packed red	23
received one	23
rag deficiency	23
recombinant human	23
rare autosomal	23
grades ii	23
pulmonary infection	23
fourteen patients	23
consolidation therapy	23
hbv reactivation	23
initial evaluation	23
first dose	23
mesenchymal stromal	23
children treated	23
randomized clinical	23
hla matching	23
review board	23
years ago	23
kinase inhibitors	23
studies suggest	23
laboratory evaluation	23
year relapse	23
specific cytotoxic	23
study demonstrates	23
risk stratification	23
also received	23
fusion protein	23
responding patients	23
related toxicities	23
published data	23
group received	23
cobe spectra	23
undergoing hematopoietic	23
humoral immunity	23
csf mobilized	23
identical donor	23
severe infection	23
secondary aml	23
leukemic blasts	23
measured using	23
may require	23
gvhd patients	23
higher nrm	23
sixteen patients	23
hla match	23
transplantation patients	23
gi gvhd	23
increased mortality	23
chest ct	23
kinase inhibitor	23
elevated ige	23
hiv infection	23
gi agvhd	23
haemorrhagic cystitis	23
clinical picture	23
organ dysfunction	23
among pediatric	23
agvhd patients	23
cell product	23
wound healing	23
based myeloablative	23
received bone	23
improve outcomes	23
gestational age	23
pain control	23
underwent haplo	23
onset noninfectious	23
human leukocyte	23
nutritional status	22
target cells	22
systemic lupus	22
old woman	22
mri showed	22
ra depleted	22
better survival	22
obliterans organizing	22
systemic corticosteroids	22
mg daily	22
gy tbi	22
graft survival	22
hematopoietic transplantation	22
hla mismatched	22
leukemia cells	22
transplant lymphoproliferative	22
ivig therapy	22
specific antibodies	22
patients submitted	22
clinically relevant	22
prognostic impact	22
reported cases	22
frequently used	22
subsequently developed	22
gvhd developed	22
fluid overload	22
ii study	22
short stature	22
important cause	22
rhinovirus infection	22
data support	22
may increase	22
showed significant	22
hematologic diseases	22
patients whose	22
undergoing autologous	22
burkitt lymphoma	22
seasonal influenza	22
molecular weight	22
immune globulin	22
lower gi	22
matched donors	22
cells obtained	22
regimen consisting	22
average number	22
igg subclass	22
european society	22
increasingly used	22
mrd group	22
recurrent bacterial	22
data collected	22
nonmyeloablative conditioning	22
normal limits	22
whole group	22
myeloid cells	22
disease activity	22
working group	22
limited number	22
end point	22
weeks post	22
received rituximab	22
recipient weight	22
quality control	22
blood volume	22
hematopoietic sct	22
wbc count	22
cytomegalovirus infection	22
cell clones	22
cytomegalovirus reactivation	22
persistent fever	22
interferon gamma	22
clinical benefit	22
pulmonary infiltrates	22
newborn screen	22
prophylaxis included	22
blood group	22
allogeneic donors	22
cell subset	22
genetic evaluation	22
mixed lymphocyte	22
significantly correlated	22
recent study	22
matched family	22
female ratio	22
low level	22
one pt	22
toxicity conditioning	22
clinical phenotypes	22
mental status	22
outpatient setting	22
patient relapsed	22
body mass	22
gvhd incidence	22
treatment lines	22
donor selection	22
assessed using	22
kidney transplant	22
every months	22
complex karyotype	22
magnetic resonance	22
highly effective	22
cerebrospinal fluid	22
scd patients	21
herpes zoster	21
autoimmune lymphoproliferative	21
clinical research	21
matched siblings	21
significant proportion	21
subgroup analysis	21
severe thrombocytopenia	21
often associated	21
treatment approach	21
linked agammaglobulinemia	21
nd cr	21
definitive diagnosis	21
negative patients	21
therapeutic strategy	21
phase trial	21
conditioning treatment	21
cell leukemia	21
median pfs	21
severe vod	21
oncology group	21
hsct patient	21
old caucasian	21
dock protein	21
low number	21
antimicrobial agents	21
stat mutations	21
recent thymic	21
amino acids	21
os rates	21
primary outcome	21
kg per	21
absolute cd	21
engraftment period	21
disease caused	21
disease course	21
targeted therapies	21
hematological disorders	21
patients developing	21
advanced phase	21
miltenyi biotec	21
adaptive immune	21
varicella zoster	21
cell number	21
unknown origin	21
healthy control	21
patient samples	21
heart failure	21
also associated	21
using flow	21
gold standard	21
related adverse	21
months respectively	21
patients remain	21
autologous bone	21
patients requiring	21
serum samples	21
pts developed	21
relapsed patients	21
patient groups	21
recipient pairs	21
cell graft	21
month period	21
genetic defects	21
absolute counts	21
infected patients	21
iv antibiotics	21
second allogeneic	21
novel mutation	21
twenty patients	21
mediated immunity	21
alkylating agent	21
thiotepa mg	21
clinical presentations	21
cancer institute	21
female presented	21
likely pathogenic	21
chemotherapy regimens	21
blood progenitor	21
year pfs	21
conditioned patients	21
cd counts	21
heart disease	21
also showed	21
high morbidity	21
transplant procedure	21
reactivation occurred	21
important risk	21
age range	21
immunocompromised hosts	21
cytometric analysis	21
brentuximab vedotin	20
real time	20
old patient	20
one died	20
relapse post	20
better outcomes	20
cmv serostatus	20
randomized study	20
two cohorts	20
leukocyte antigen	20
cancer treatment	20
intravenous busulfan	20
ferritin level	20
years later	20
depleted graft	20
longer time	20
ecp therapy	20
testing revealed	20
data suggests	20
critical care	20
seven pts	20
relapse progression	20
among hsct	20
days prior	20
years os	20
first allogeneic	20
csf mobilization	20
immunodeficiency disorder	20
adv infection	20
studies revealed	20
mismatched donors	20
hl patients	20
donor transplant	20
cell acute	20
enrolled patients	20
larger cohort	20
unrelated bone	20
haploidentical sct	20
cml patients	20
pseudomonas aeruginosa	20
may play	20
venous catheter	20
treatment group	20
unrelated hsct	20
first years	20
young age	20
enzyme replacement	20
remains unknown	20
genes involved	20
received stem	20
pulmonary hypertension	20
animal models	20
day mortality	20
resonance imaging	20
cmv seropositive	20
csf administration	20
received atg	20
disease severity	20
primary objective	20
cy group	20
one episode	20
without agvhd	20
ms ms	20
wild type	20
sore throat	20
cell response	20
severe anemia	20
blood cd	20
refractory aml	20
cmv status	20
von willebrand	20
autoimmune manifestations	20
possible role	20
past years	20
small sample	20
viral culture	20
days respectively	20
high doses	20
functional studies	20
allergy immunology	20
neutrophil counts	20
treatment regimens	20
small bowel	20
treatment response	20
cell types	20
log rank	20
trec levels	20
well described	20
pneumocystis jiroveci	20
initially presented	20
performed according	20
disease phase	20
posttransplant cyclophosphamide	20
cells compared	20
received conditioning	20
rheumatoid arthritis	20
pbsc collection	20
data analysis	20
cardiovascular disease	20
cik cell	20
beta thalassemia	20
clinimacs prodigy	20
candida albicans	20
lof stat	20
endothelial damage	20
cell expansion	20
aml cells	20
respiratory disease	20
groups according	20
including patients	20
control measures	20
case description	20
ferritin levels	20
received cyclosporine	20
oral care	20
reference range	20
acquired respiratory	20
myelomonocytic leukemia	20
one study	20
literature review	20
large cell	20
negative bacteria	20
ivig treatment	20
antimicrobial prophylaxis	20
thalassemia patients	20
donor engraftment	20
busulfan mg	20
risk features	20
conditioning intensity	20
malignant disorders	19
reported case	19
clinical condition	19
observation period	19
threatening infections	19
short term	19
rare complication	19
first reported	19
portal hypertension	19
transplantation outcomes	19
ada deficiency	19
physical functioning	19
may reduce	19
marrow cells	19
disease stage	19
clinical use	19
attributable mortality	19
received either	19
cell compartment	19
relatively low	19
cell engraftment	19
control arm	19
cell immune	19
hospital medical	19
hematology department	19
mud hsct	19
vaccine responses	19
poor risk	19
dose reduction	19
death due	19
virus type	19
infections caused	19
nkt cells	19
vascular malformations	19
without atg	19
heart transplant	19
novel therapeutic	19
month follow	19
extensive cgvhd	19
hct patients	19
adult hsct	19
hematopoietic progenitor	19
nucleated cell	19
ruxolitinib treatment	19
analysis identified	19
central line	19
allo hct	19
leukemia relapse	19
months following	19
control groups	19
patients including	19
induced lung	19
bmt unit	19
cd levels	19
times daily	19
done using	19
mud mmud	19
hyper ige	19
cb units	19
nadph oxidase	19
flu mel	19
improve outcome	19
pts underwent	19
within weeks	19
clinical study	19
blood flow	19
ebv pcr	19
consanguineous parents	19
antiviral agents	19
aspergillus species	19
csf alone	19
congenital neutropenia	19
alkylating agents	19
treatment may	19
primary engraftment	19
patients admitted	19
disseminated bcg	19
hla mismatch	19
molecular diagnosis	19
received autologous	19
cy tbi	19
evaluation showed	19
cell lymphomas	19
increased frequency	19
plerixafor group	19
diseases society	19
infection therapies	19
year follow	19
ccr expression	19
cell boost	19
cmv pneumonitis	19
tcr alpha	19
weeks later	19
beam conditioning	19
one third	19
factor associated	19
clinical management	19
igm levels	19
invasive candidiasis	19
useful tool	19
cellular immunity	19
best response	19
frequent complication	19
tki therapy	19
ebmt centers	19
patients given	19
first transplant	19
also known	19
critical role	19
cov infection	19
highest risk	19
male presented	19
cy mg	19
four months	19
recombinant factor	19
secondary malignancy	19
pleural effusion	19
five cases	19
bcg infection	19
late complications	19
hospital admission	19
hla disparity	19
marrow aspirate	19
still remains	19
significant factor	18
well defined	18
clostridium difficile	18
hepatic vod	18
toxicity profile	18
improved os	18
analysis using	18
congenital heart	18
year nrm	18
two decades	18
blood grafts	18
light chain	18
rna sequencing	18
stage ii	18
disease prophylaxis	18
patients using	18
higher relapse	18
signaling pathways	18
two days	18
pandemic influenza	18
phox cgd	18
follicular lymphoma	18
cytogenetic abnormalities	18
recessive disorder	18
gut gvhd	18
chronic kidney	18
categorical variables	18
renal dysfunction	18
patients develop	18
infections due	18
function mutation	18
poor response	18
normal karyotype	18
revealed low	18
igg trough	18
related deaths	18
cell harvest	18
second complete	18
celiac disease	18
different clinical	18
lower extremities	18
interstitial pneumonitis	18
advanced stage	18
cell aplasia	18
transplant course	18
received reduced	18
four weeks	18
studied patients	18
cause severe	18
ige levels	18
clinical history	18
mantle cell	18
positive selection	18
control study	18
systemic treatment	18
growth failure	18
treatment protocols	18
acceptable toxicity	18
preemptive treatment	18
may benefit	18
survival outcomes	18
patients respectively	18
adult patient	18
clinical parameters	18
kg iv	18
absolute numbers	18
cytomegalovirus disease	18
patient survival	18
primary infection	18
recurrent skin	18
national university	18
allowed us	18
prospective clinical	18
mass index	18
bal fluid	18
cell sorting	18
different types	18
pts treated	18
higher proportion	18
rabbit anti	18
endothelial dysfunction	18
cns involvement	18
infection may	18
day survival	18
mycobacterial infections	18
related death	18
cause mortality	18
treatment strategy	18
immunosuppressed patients	18
patients except	18
risk assessment	18
analysis demonstrated	18
metapneumovirus infection	18
adult recipients	18
using high	18
blood products	18
hepatocellular carcinoma	18
clinical efficacy	18
induction regimens	18
vod prophylaxis	18
retrospective data	18
ectodermal dysplasia	18
food allergy	18
commercially available	18
death occurred	18
may serve	18
initial diagnosis	18
hsct group	18
neutropenic period	18
several months	18
successful engraftment	18
received two	18
developed vod	18
antifungal agents	18
regulatory cells	18
better understanding	18
tertiary care	18
three different	18
analyzed data	18
skin involvement	18
patients characteristics	18
influenza infection	18
previous treatment	18
marrow transplants	18
node biopsy	18
rsv pneumonia	18
donor hematopoietic	18
organ toxicity	18
ebv dna	18
may affect	18
tbi cy	18
hsct recipient	18
failure syndromes	18
killer cells	18
birth weight	18
non relapse	18
serum immunoglobulins	18
factors affecting	17
normal lymphocyte	17
vs months	17
ursodeoxycholic acid	17
ecp procedures	17
heterozygous missense	17
viral reactivations	17
herpes virus	17
aggressive lymphoma	17
based ric	17
ribavirin therapy	17
first weeks	17
telomere length	17
laboratory parameters	17
collected cd	17
pbsc grafts	17
cd dim	17
igm mg	17
taken together	17
hemopoietic stem	17
normal controls	17
irb approval	17
major complications	17
bladder irrigation	17
sustained engraftment	17
randomized trials	17
vs vs	17
mobilization regimen	17
laboratory tests	17
laboratory studies	17
median total	17
diagnostic yield	17
gata mutation	17
crucial role	17
common complication	17
results confirm	17
prophylaxis regimens	17
conventional treatment	17
responded well	17
inflammatory markers	17
urine samples	17
recently reported	17
previously unreported	17
underwent myeloablative	17
spleen size	17
dna binding	17
effective therapeutic	17
written informed	17
induction failure	17
likely due	17
autologous cd	17
ebmt risk	17
eighteen patients	17
severe congenital	17
died within	17
one grade	17
also included	17
risk index	17
different conditioning	17
delayed engraftment	17
term disease	17
transplant doi	17
received tbi	17
mortality due	17
improved outcomes	17
three days	17
jc virus	17
elevated igg	17
extremely rare	17
autologous pbsct	17
lower levels	17
low iga	17
lung cancer	17
donor graft	17
pediatric aml	17
cells may	17
third party	17
receiving chemotherapy	17
group consisted	17
leukemia free	17
will allow	17
cell deficiency	17
without increasing	17
non malignant	17
cell maturation	17
prospective trial	17
sequential conditioning	17
relapse following	17
second transplantation	17
antiviral prophylaxis	17
associated hemorrhagic	17
gp phox	17
study comparing	17
type diabetes	17
oral hygiene	17
active infection	17
two consecutive	17
effective strategy	17
gastrointestinal symptoms	17
dried blood	17
conditioning chemotherapy	17
replete haplo	17
three weeks	17
dendritic cell	17
larger studies	17
treatment outcomes	17
treatment regimen	17
cell rescue	17
significantly less	17
less severe	17
year ci	17
acute lung	17
health outcomes	17
improve survival	17
humoral immune	17
severe immune	17
preparative regimens	17
immunology clinic	17
one day	17
culture system	17
initially treated	17
immunologic evaluation	17
left ventricular	17
associated thrombotic	17
showed severe	17
associated mortality	17
dismal prognosis	17
linear regression	17
reduced dose	17
suitable donor	17
lymphoid malignancies	17
primary care	17
confi rmed	17
ground glass	17
key role	17
significant cause	17
helper cells	17
immunosuppression consisted	17
chemotherapy plus	17
cd monoclonal	17
specific immune	17
undergone hsct	17
positive correlation	17
low doses	17
immunodeficiency disorders	17
iron deficiency	17
determined using	17
sectional study	17
significantly shorter	17
total parenteral	17
antibody production	17
blood transfusions	17
cancer diagnosis	17
interval ci	17
every days	17
engraftment rate	17
regimen followed	17
patients post	17
examination showed	17
myelodysplastic syndromes	17
oral health	17
risk mds	17
os vs	17
escalating doses	17
small molecule	17
strongly associated	17
patients present	17
jak inhibitor	17
median neutrophil	17
high prevalence	17
patients completed	17
initial treatment	17
cmv infections	17
months vs	17
treated group	16
tbi based	16
atg mg	16
steady state	16
laboratory values	16
marrow donor	16
survival curves	16
etoposide mg	16
severe forms	16
risk hematologic	16
major severe	16
lymphoblastic leukaemia	16
compassionate use	16
median months	16
evaluated using	16
pb cd	16
lower compared	16
proportional hazard	16
mental health	16
hsct program	16
cytokine levels	16
early stages	16
antibacterial prophylaxis	16
may present	16
treated mice	16
cmv reactivations	16
hematopoietic reconstitution	16
kg dose	16
reducedintensity conditioning	16
transplant relapse	16
transfusion dependent	16
alkaline phosphatase	16
hsct outcomes	16
four pts	16
large number	16
report two	16
colony forming	16
malignant cells	16
received additional	16
haemopoietic stem	16
index patient	16
ro memory	16
clin immunol	16
within years	16
two cycles	16
iv gvhd	16
short tandem	16
lymphoblastic lymphoma	16
mg twice	16
kidney function	16
cmv serology	16
positive mrd	16
pnp deficiency	16
nsg mice	16
using different	16
treatment groups	16
venous catheters	16
received fludarabine	16
cells within	16
chest pain	16
free relapse	16
recurrent episodes	16
second dose	16
fi brosis	16
autoimmune thyroiditis	16
ctla haploinsufficiency	16
arterial hypertension	16
chronic rejection	16
patients achieving	16
igg positive	16
late relapse	16
gvhd grades	16
patients enrolled	16
cmv pcr	16
high number	16
cell cycle	16
pts undergoing	16
molecular analysis	16
previously demonstrated	16
achieving cr	16
transplantation background	16
vast majority	16
lactate dehydrogenase	16
acute grade	16
primary human	16
therapeutic drug	16
related infections	16
complications following	16
younger age	16
abo incompatibility	16
mhc class	16
oral ulcers	16
prolonged neutropenia	16
mean follow	16